Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Ispronicline (Targacept).

¹In Silico Biosciences Inc, 3741 Walnut Street #609, Philadelphia, PA 19104, USA. Hugo-Geerts@In-Silico-Biosciences.com

Current Opinion in Investigational Drugs (London, England : 2000)

|January 24, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology study.

Frontiers in pharmacology·2026

Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Interactions of Therapeutic Antibodies With Presynaptically-Released Misfolded Proteins in Neurodegenerative Diseases. A Spatial Monte-Carlo Simulation Study.

CPT: pharmacometrics & systems pharmacology·2025

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Targacept is developing ispronicline, a novel nicotinic acetylcholine ligand, for cognitive impairment. This oral treatment shows potential for non-Alzheimer's dementias and Alzheimer's disease.

Area of Science:

Neuroscience
Pharmacology

Background:

Cognitive impairment affects numerous individuals, with limited treatment options.
Nicotinic acetylcholine receptors play a crucial role in cognitive function.

Purpose of the Study:

To evaluate ispronicline as a potential oral therapeutic for cognitive impairment.
To investigate the efficacy of ispronicline in non-Alzheimer's dementias and Alzheimer's disease.

Main Methods:

Development of ispronicline, a novel nicotinic acetylcholine ligand.
Preparation for Phase II clinical trials in patients with mild-to-moderate Alzheimer's disease.

Main Results:

Ispronicline is the lead compound in a series of nACh ligands.
The drug is being developed as an oral treatment.

Related Experiment Videos

Conclusions:

Ispronicline holds promise for treating cognitive deficits.
Further clinical investigation is warranted for Alzheimer's disease and other dementias.